Board of Directors

Ekaterina Malievskaia MD MScPH

Chief Innovation Officer
and Co-founder

Dr Ekaterina Malievskaia leads Research and Development at COMPASS.

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.

We have created COMPASS to improve patients’ access to innovation in mental health. Through our personal experiences, we have learned how challenging it could be to find the right treatment and right expertise in time. We also learned that it could make all the difference in the outcomes. We walked that path so others don’t have to.

George Goldsmith

Executive Chairman, Chief Executive Officer, and Co-founder

George is an entrepreneur dedicated to bringing about positive change in society with particular focus on health and wellbeing.

George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science. His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks' Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.

I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.

Annalisa Jenkins MBBS

Independent Director

Annalisa is a senior biotech executive, the Executive Chairman at Vium and a Non-Executive Director at eight other biotech companies.

Annalisa was previously Head of R&D at Merck Serono and Global Medical Senior Vice-President at Bristol-Myers Squibb. She is the CEO of PlaqueTec - a company driving the future of personalised medicine in coronary artery disease, in addition to chairing or serving on the boards of a number of private and public companies in the life sciences industry, located in the U.S. and U.K.

Thomas Lönngren

Independent Director

Thomas Lönngren is a senior regulatory Executive, and served as Executive Director of the European Medicines Agency (EMA) from 2001-2010.

Thomas is currently Director at Pharma Executive Consulting and Strategic Advisor at the NDA Group. His greatest achievement is heading the European Medicines Agency for 10 years taking it from a relatively unknown agency in 2001 to become recognised together with the US FDA as a world leader in drug regulation. Based on his extensive experience and knowledge of drug/device regulation, approval, market access, management, strategy and leadership, he currently advises pharmaceutical companies worldwide on drug development with a focus on regulatory and market access. He also serves as a non executive board member, participates in scientific Advisory Boards and frequently speaks at conferences around the world.

David Norton

Independent Director

David Norton is a senior Biopharma Executive, and the former Company Group Chairman of Global Pharmaceuticals at Johnson & Johnson.

David is currently a Director at two other life sciences companies. He has also been a standout as Board member and benefactor of Alliance For Aging Research, a national non-profit organisation, which seeks research-based, innovative solutions to the health problems of aging populations.

Florian Brand

Member of Board of Directors and Founding Seed and Series A Investor

Florian is the Co-Founder and Chief Executive Officer of ATAI Life Sciences AG, a Seed and Series A investor in COMPASS.

Florian focuses on the operational execution of early-stage discovery and drug development programmes. He is currently interim CEO at Perception Neuroscience, one of ATAI's platform companies. ATAI is a global biotech company builder that leverages a decentralised, technology- and data-driven platform model to serve millions of people suffering with mental health disorders. Prior to ATAI, Florian was Co-founder and MD at Springlane, a growing technology company in the German consumer space. His past experiences include roles at Rocket Internet, Allianz, and the Tanzanian German Program to Support Health. Florian studied economics and management.

We know that the unmet medical need of depression is increasingly urgent. With more than 300 million people living with depression worldwide – a third of whom do not respond to standard treatments – we cannot wait to take action. Together with COMPASS and other leaders in the field, ATAI is committed to bridging the gap between what people living with mental health illnesses need, and what the system can currently provide.

Paolo Siviero

Member of Board of Directors and Series A Investor

Paolo is Head of Investments for Principia III, the first Italian VC and PE fund entirely dedicated to life sciences investments, and formerly Head of Strategy and Policy on Medical Products Area at AIFA (Italian regulator).  

At Agenzia Italiana del Farmaco (AIFA), Paolo was responsible for establishing prices and refundability of medicines, evaluating HTAs and checking pharmaceutical expenditures. Prior to joining AIFA, he was Chairman of MEDEV Group and a Board Member of the European Medicines Agency (EMA). Paolo has extensive experience investing in life sciences companies, including AnaBios, Enterome, and Ixaltis. For more information about Principia, please visit their website:

Srinivas Rao, MD, PhD

Member of Board of Directors and Series A Investor

Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG and the former CEO of Kyalin Biosciences.

Srinivas Rao has been the Chief Medical Officer of multiple biotech companies, including Axial Biotheraputics, Inc., Deposed, Inc. and Kayla Pharmaceuticals. He holds an MD in Internal Medicine from Yale University School of Medicine and a PhD in Neuropharmacology from Yale University. Srinivas has also been an advisory board member to UCSD SDTA and HUYA Bioscience international.